CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 242 enrolled
Drug / intervention
Mobile health application +1 moreother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05748639
NCT05748639Phase 3Completed

Randomized Controlled Trial of an Integrated Digital Cognitive-Behavioral Therapy (CBT) and Pharmacotherapy Intervention for Adults With Alcohol Use Disorders

Quit Genius·interventional·Posted Mar 1, 2023·Updated Nov 20, 2025

In Brief

A Phase 3 clinical trial evaluating Mobile health application and Medical Management for Alcohol Use Disorder. Completed, enrolled 242 participants across 1 site.

Detailed Summary

This study is a two-arm randomized clinical trial comparing the Quit Genius intervention for alcohol use disorder (QG-A) to usual care (TAU), comprising medical management of alcohol use disorders with pharmacotherapy. Participants (N=300) will be randomly assigned to either QG-A or TAU, and will be assessed at baseline, monthly throughout the 6-month intervention phase and at 3 and 6 months post-treatment, to investigate the impact of QG-A, relative to TAU on alcohol use, psychological symptoms, and health service utilization. The primary aim of the study is to evaluate the efficacy of QG-A, relative to TAU in reducing alcohol use and associated mental health and functional outcomes. A secondary aim is to examine the cost-effectiveness of QG-A, including cost savings and impact on productivity.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--

Timeline

Phase 3CompletedFinished
2023202420252026
First PostedMar 1, 2023
Enrollment StartJan 1, 2023
Primary CompletionJun 15, 2025
Study CompletionJul 15, 2025
TodayJul 2, 2026
Enrollment to primary: 2.5 yearsPosted 3.3 years ago

Interventions

Mobile health applicationother

Participants randomized to receive the QG-A (Experimental) intervention will receive monthly appointments with a medical provider, access to naltrexone, and weekly and bi-weekly appointments with a licensed clinical counselor through an integrated digital health application.

Medical Managementother

Participants randomized to receive the MM (Control) intervention will receive monthly appointments with a medical provider and access to naltrexone.